NeuroMetrix,
Inc. (Nasdaq: NURO), a medical device company focused on management
of chronic pain and peripheral neuropathies, today announced that Shai
N. Gozani M.D., Ph.D., President and Chief Executive Officer, is
scheduled to speak at the Rodman & Renshaw Annual Global Investment
Conference at the Millennium Broadway Hotel, New York, NY on September
8-10, 2013. Dr. Gozani intends to provide an update on the Company’s
business activities including the SENSUS™ Pain Management System, which
is an electrical nerve stimulator uniquely designed for controlling
chronic pain caused by diabetic neuropathy.
NeuroMetrix's presentation is scheduled for Monday, September 9, 2013 at
2:50 pm (Eastern Daylight Time) in Room 7.03, 7th Floor. A
live audio webcast will be available on the investor relations section
of the corporate website - www.neurometrix.com.
This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home
use and point-of-care devices for the treatment and management of
chronic pain and peripheral neuropathies. The Company is presently
focused on diabetic neuropathies, which affect over 50% of people with
diabetes. If left untreated, diabetic neuropathies trigger foot ulcers
that may require amputation and cause disabling chronic pain. The annual
cost of diabetic neuropathies has been estimated at $14
billion in the United States. The company markets the SENSUS™ Pain
Management System for treating chronic pain, focusing on physicians
managing patients with painful diabetic neuropathy. The company also
markets the DPNCheck® device, which is a rapid, accurate, and
quantitative point-of-care test for diabetic neuropathy. This product is
used to detect diabetic neuropathy at an early stage and to guide
treatment. For more information, please visit http://www.neurometrix.com.
Copyright Business Wire 2013